Initiation Reports

(For full reports click the company logo)

Coverage Universe Updates

March 7, 2021 Update  click here

July 26, 2020 Update  click here

Jan 16, 2020 Update  click here

Modular Medical

June 7, 2021

As the company “Pivots” from development to commercial stage, we believe shareholders could reap returns as high as 7-8x from the current price.

Processa Pharma

February 22, 2021

We believe
by 2023, Processa could have one, or more, programs in Ph3, warranting a substantial bump in valuation, which we estimate to be >$500mm.

Ocuphire Pharma

November 9, 2020

Low Science / High Science, Low Risk / High Risk, Ocuphire has a little of everything, heading into a data-rich 2021.

Perimeter Medical

October 21, 2020

We believe Perimeter’s widefield OCT unit, OTIS, can be a solution to the reexcision “epidemic” in breast conservation surgery.

Delcath Systems

May 29, 2020

We believe Delcath’s $50mm market cap today is a reflection of its colorful past, not its bright future.

TLC

April 27, 2020

We believe TLC can achieve a market cap of ~400mm this year based on positive TLC590 Ph2 data, and growing investor enthusiam towards the completion of the TLC599 Ph3 study.

Xenon Pharma

October 16, 2019

We believe through clinical success with their lead assets, XEN496 and XEN1101, Xenon can achieve a market cap of >$1 billion by 2021, reflecting a nearly 4.5x multiple from its recent share price of $8.35 (10/11/19).